Popular terms

Codon topics
Hydrocodone
Nucleic Acid
Acetaminophen
Carboxylic Acid
Benzoic Acid
Genetically
Recombinant
Amino Acid
Nucleotide
Reverse Transcriptase Inhibitors
Reverse Transcriptase Inhibitor
Reverse Transcriptase
Antibodies
Base Sequence
Replication

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Codon patents



      

This page is updated frequently with new Codon-related patent applications.




Date/App# patent app List of recent Codon-related patents
02/04/16
20160032254 
 Aav vectors produced by insect cells comprising rep52 and rep78 coding sequences with differential codon biases patent thumbnailnew patent Aav vectors produced by insect cells comprising rep52 and rep78 coding sequences with differential codon biases
The present invention relates to production of proteins in insect cells whereby repeated coding sequences are used in baculoviral vectors. In particular the invention relates to the production of parvoviral vectors that may be used in gene therapy and to improvements in expression of the viral rep proteins that increase the productivity of parvoviral vectors..
Uniqure Ip B.v.


02/04/16
20160030419 
 Once-a-day oxycodone formulations patent thumbnailnew patent Once-a-day oxycodone formulations
The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean c24/cmax oxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients and methods thereof.. .
Purdue Pharma L.p.


01/28/16
20160022805 
 Computationally optimized broadly reactive antigens for human and avian h5n1 influenza patent thumbnailComputationally optimized broadly reactive antigens for human and avian h5n1 influenza
Described herein is the generation of optimized h5n 1 influenza ha polypeptides for eliciting a broadly reactive immune response to h5n1 influenza virus isolates. The optimized ha polypeptides were developed through a series of ha protein alignments, and subsequent generation of consensus sequences, based on human and avian h5n1 isolates.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education


01/21/16
20160017341 
 Universal protein overexpression tag comprising ramp function, and application thereof patent thumbnailUniversal protein overexpression tag comprising ramp function, and application thereof
Provided is a ramp tag capable of solving instability in translation rate resulting from poor compatibility between codons in a foreign gene and a host when expressing a recombinant protein in e. Coli.
Industry Foundation Of Chonnam National University


01/21/16
20160016965 
 Novel mixed μ agonist/ δ antagonist opioid analgesics with reduced tolerance liabilities and uses thereof patent thumbnailNovel mixed μ agonist/ δ antagonist opioid analgesics with reduced tolerance liabilities and uses thereof
An opioid narcotics used for the treatment of moderate-to-severe pain that primarily exert their analgesic effects through μ receptors. Although, traditional μ agonists can cause undesired side effects, including tolerance, addition of δ antagonists can attenuate said side effects.
West Virginia University


01/21/16
20160015802 
 Compositions and methods to treat aids patent thumbnailCompositions and methods to treat aids
Polyvalent, primary isolate nucleic acid compositions for inducing an immune response against hiv are disclosed. The compositions and methods described herein are for the use of a nucleic acid composition that encodes one or more different hiv envelope glycoproteins.
University Of Massachusetts


01/14/16
20160010111 
 Production methods patent thumbnailProduction methods
The present invention provides methods of reducing the levels of a titratable selectable pressure required, the number of amplification cycles, and the time taken to generate protein expressing cell lines by altering the codons of the desired open-reading-frames. Through the use of codon adaptation for this purpose the methods of the invention consistently provide sufficient yields in faster time frames saving many weeks in cell line development activities.
Glaxo Group Limited


01/07/16
20160002616 
 Genes with codon mutations encoding xylanase patent thumbnailGenes with codon mutations encoding xylanase
The present disclosure provides for a polynucleotide sequences encoding a xylanase. More specifically, the present disclosure provides for polynucleotide sequences with codon mutations encoding a xylanase..
Basf Enzymes Llc


12/24/15
20150368622 
 Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization patent thumbnailAttenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization
Described herein are rsv polynucleotide sequences that make use of multiple codons that are containing silent nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce a numerous synonymous codons into the genome. Due to the large number of defects involved, the attenuated viruses disclosed herein provide a means of producing attenuated, live vaccines against rsv..
The United Of America, As Represented By Secretary, Department Of Health And Human Services


12/17/15
20150361158 
 Optimized factor viii gene patent thumbnailOptimized factor viii gene
The present invention provides codon optimized factor viii sequences, vectors and host cells comprising codon optimized factor viii sequences, polypeptides encoded by codon optimized factor viii sequences, and methods of producing such polypeptides.. .
Biogen Ma Inc.


12/10/15
20150353938 

Codon optimized nucleic acid encoding a retinitis pigmentosa gtpase regulator (rpgr)


This invention relates generally to a codon optimized nucleic acid encoding a retinitis pigmentosa gtpase regulator (rpgr) protein. The nucleic acid has enhanced stability during plasmid production relative to a wildtype cdna encoding the rpgr protein.
Applied Genetic Technologies Corporation


12/10/15
20150352136 

Novel aminoglycosides and uses thereof in the treatment of genetic disorders


A new class of paromomycin-derived aminoglycosides, which exhibit efficient stop-codon mutation suppression activity, low toxicity and high selectivity towards eukaryotic cells are provided. Also provided are chemical and chemo-enzymatic processes of preparing these paromomycin-derived aminoglycosides and intermediates thereof, as well as pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders..
Technion Research & Development Foundation Limited


12/03/15
20150344930 

Codon-optimized recombinant phage and methods of using same


Composition and methods for the detection of one or more target microbe(s) are provided. Compositions of the disclosure include at least one recombinant phage capable of infecting a target microbe, said phage comprising at least a capsid protein sequence, a ribosome binding site, and a codon-optimized marker.
Sample6 Technologies, Inc.


11/26/15
20150335759 

Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof


The presently described technology provides methods of treating a patient having moderate to severe pain, narcotic or opioid abuse or narcotic or opioid withdrawal. The presently described methods are carried out by comprising administering to the patient a pharmaceutically effective amount of a composition comprising acetaminophen and benzoate-hydrocodone hydrochloride.
Kempharm, Inc.


11/26/15
20150335639 

Treating pain in patients with hepatic impairment


An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules.
Pernix Ireland Pain Limited


11/19/15
20150329854 

Method of synthesis of gene library using codon randomization and mutagenesis


Proposed is a method of easily finding an error during analysis of various library sequences of nucleic acid base sequences after synthesizing a gene library using a combination of three nucleic acid base sequences (codon) translated into the same protein. This shows that it is possible to create a gene library having the same protein sequence but different nucleic acid base sequences.
Celemics, Inc.


11/19/15
20150328247 

Agents for treating genetic diseases resulting from nonsense mutations, and methods for identifying the same


Disclosed is treatment of genetic neurodegenerative or neurodevelopmental diseases that are caused by or associated with nonsense mutations or premature termination codons using macrolides. Further disclosed are methods for identifying agents that induce read-through of nonsense mutations and premature termination codons and uses thereof..
Ramot At Tel-aviv University Ltd.


11/12/15
20150320686 

Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer


The disclosed invention is drawn to pharmaceutical tablets that provide delivery of active agents having at least three oxygen-containing groups, as well as a second active ingredient. Non-limiting examples of three oxygen-containing group active agents include guaifenesin, codeine, hydrocodone, and their pharmaceutically acceptable salts.

10/29/15
20150307912 

Site-specific incorporation of phosphoserine into proteins in escherichia coli


Nucleic acids encoding mutant elongation factor proteins (ef-sep), phosphoseryl-trna synthetase (seprs), and phosphoseryl-trna (trnasep) and methods of use in site specific incorporation of phosphoserine into a protein or polypeptide are described. Typically, seprs preferentially aminoacylates trnasep with o-phosphoserine and the trnasep recognizes at least one codon such as a stop codon.
Yale University


10/15/15
20150293023 

Systems and methods for measuring translation of target proteins in cells


The present invention relates to systems and methods for measuring the rate of translation of a target protein in cells, which are based on the detection of translation of one or more predetermined codon pairs during synthesis of the target protein. The detection is provided by a fret signal emitted from labeled trna molecules which are juxtaposed during synthesis of the protein..

10/08/15
20150284402 

Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof


Solid forms of certain opioid agonists are provided herein. Methods of preparing the solid forms, methods of using the solid forms, and pharmaceutical compositions comprising the solid forms are also provided herein..

10/08/15
20150283267 

Vectors for liver-directed gene therapy of hemophilia and methods and use thereof


The present invention relates to vectors containing liver-specific regulatory sequences and codon-optimized factor ix or factor viii genes, methods employing these vectors and uses of these vectors. Expression cassettes and vectors containing these liver-specific regulatory elements and codon-optimized factor ix or factor viii genes are also disclosed.

10/01/15
20150273026 

Clinical applications for recombinant human mxa protein


Full length mxa constructs and truncated mxa constructs produce human mxa protein in e. Coli.
Rapid Pathogen Screening, Inc.


09/24/15
20150265598 

Oxycodone compositions


In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .
Rhodes Technologies


09/24/15
20150265597 

Oxycodone compositions


In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .
Rhodes Technologies


09/24/15
20150265537 

Controlled release hydrocodone formulations


A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.. .
Purdue Pharma L.p.


09/17/15
20150259721 

Cell lines


There is provided inter alia a process for stabilizing a eukaryotic cell line which expresses pylrs and trnapyl and which is suitable for incorporation of a gene encoding a target protein containing one or more non-natural amino acids encoded by a nonsense codon which comprises culturing said cell line under conditions in which the adverse effect of trnapyl expression on cell viability and/or cell growth is reduced or eliminated.. .
Allozyne, Inc.


09/17/15
20150259664 

Proteolytic inactivation of select proteins in bacterial extracts for improved expression


The present disclosure provides modified proteins that are capable of being cleaved by the protease ompt1. The proteins can be modified in an exposed surface motif to incorporate ompt1 cleavage sites.
Sutro Biopharma, Inc.


09/17/15
20150259355 

Process for improved opioid synthesis


Compounds and compositions for use as starting materials or intermediate materials in the preparation of opioids including, e.g., oxycodone base and/or an oxycodone salt; processes for preparing these compounds and compositions; uses of these compounds and compositions in the preparation of apis and pharmaceutical dosage forms; and uses of said apis and pharmaceutical dosage forms in the treatment of medical conditions.. .
Rhodes Technologies


09/17/15
20150258186 

Nucleic acid molecule vaccine compositions and uses thereof


The present disclosure relates to nucleic acid vaccine compositions and methods for preventing or treating pathological conditions, such as cancer or infectious disease. Further, the disclosure provides methods for more efficient production of antigens via mrna containing one or more non-conventional start codons to promote multiplex initiation of translation in eukaryotic cells..
Tapimmune Inc.


09/17/15
20150258090 

Controlled release hydrocodone formulations


A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.. .
Purdue Pharma L.p.


09/17/15
20150258089 

Controlled release hydrocodone formulations


A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.. .
Purdue Pharma L.p.


09/17/15
20150258086 

Oxycodone compositions


In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.. .
Rhodes Technologies


09/10/15
20150252052 

Processes for making hydrocodone, hydromorphone and their derivatives


Improved processes for making hydrocodone and hydromorphone as well as their 8,14-dihydrothebaine and 8,14-dihydrooripavine derivatives and salts are disclosed.. .
Johnson Matthey Public Limited Company


09/10/15
20150250866 

Live attenuated antigenically marked classical swine fever vaccine


Controlling classical swine fever virus (csfv) involves either prophylactic vaccination or non-vaccination and elimination of infected herds depending on the epidemiological situation. Marker vaccines allowing distinction between naturally infected from vaccinated swine could complement “stamping out” measures.
The United States Of America, As Represented By The Secretary Of Agriculture


09/10/15
20150250151 

Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same


A genetically modified non-human animal is provided, wherein the non-human animal expresses an antibody repertoire capable of ph dependent binding to antigens upon immunization. A genetically modified non-human animal is provided that expresses human immunoglobulin light chain variable domains derived from a limited repertoire of human immunoglobulin light chain variable gene segments that comprise histidine modifications in their germline sequence.
Regeneron Pharmaceuticals, Inc.


09/03/15
20150246961 

Method for the expression of polypeptides using modified nucleic acids


Herein is reported a method for recombinantly producing a polypeptide in a cell comprising the step of cultivating a cell which comprises a nucleic acid encoding the polypeptide, and recovering the polypeptide from the cell or the cultivation medium, wherein each of the amino acid residues of the polypeptide is encoded by at least one codon, whereby the different codons encoding the same amino acid residue are combined in one group and each of the codons in a group is defined by a specific usage frequency within the group, whereby the sum of the specific usage frequencies of all codons in one group is 100%, and wherein the usage frequency of a codon in the polypeptide encoding nucleic acid is about the same as its specific usage frequency within its group.. .
Hoffmann-la Roche Inc.


09/03/15
20150246083 

Genetically modified probiotic for the treatment of phenylketonuria (pku) disease


A gmp adapted to provide the pal gene for the treatment of pku when administered orally. The gmp of the present invention may include a probiotic, a pal gene to be expressed using the probiotic, wherein the pal gene is functionally attached to a promoter and a ribosome binding site, and may be codon-optimized for expression in a certain host organism.
University Of North Texas


09/03/15
20150246034 

Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia


The present disclosure provides extended release pharmaceutical compositions comprising oxycodone and acetaminophen that produce a quick initial onset of analgesia, yet, maintain analgesia for about 12 hours after administration of the composition to a subject in need thereof. The pharmaceutical compositions disclosed herein also reduce the levels of acetaminophen in a subject's blood near the end of the dosing interval because the acetaminophen released by the pharmaceutical composition is being eliminated by a subject's body faster than it is being absorbed..
Mallinckrodt Llc


08/27/15
20150240280 

Methods for in vitro joining and combinatorial assembly of nucleic acid molecules


The present invention relates to methods of joining two or more double-stranded (ds) or single-stranded (ss) dna molecules of interest in vitro, wherein the distal region of the first dna molecule and the proximal region of the second dna molecule of each pair share a region of sequence identity. The method allows the joining of a large number of dna fragments, in a predetermined order and orientation, without the use of restriction enzymes.
Synthetic Genomics, Inc.


08/27/15
20150238418 

Controlled release hydrocodone formulations


A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.. .
Purdue Pharma L.p.


08/20/15
20150231163 

Composition for preventing or treating colitis


The present invention relates to a novel use of an anemarrhena asphodeloides bunge extract and the like, and provides a composition for preventing or treating colitis, including an anemarrhena asphodeloides bunge extract, a fraction thereof or a compound isolated therefrom as an active ingredient. In addition, the present invention relates to a novel use of a combined extract of medicinal herbs, and provides a composition for preventing or treating colitis, including an anemarrhena asphodeloides bunge extract, a galla rhois extract, a codonopsis lancellata extract, and the like as active ingredients, or including an anemarrhena asphodeloides bunge extract, a coptis japonica makino extract, and the like as active ingredients.
University-industry Cooperation Group Of Kyung Hee University


08/20/15
20150231131 

Once-a-day oxycodone formulations


The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean c24/cmax oxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients and methods thereof.. .
Purdue Pharma L.p.


08/20/15
20150231083 

Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition


An object is to provide a hydromorphone hydrochloride- or oxycodone hydrochloride hydrate-containing sustained-release pharmaceutical composition for oral administration that reliably exhibits its main pharmacological effect and has excellent formulation stability that avoids dose dumping of the principal drug, such as alcohol resistance. The present invention provides a sustained-release pharmaceutical composition comprising (a) hydromorphone hydrochloride or oxycodone hydrochloride hydrate, (b) hydroxypropyl methylcellulose acetate succinate having a median size (d50) of 40 μm or smaller, (c) hydroxypropyl cellulose, and (d) a saccharide, wherein the content ratio of the component (c) to the component (b) by weight in the composition, (c)/(b), is 11/3 to 3/11..
Daiichi Sankyo Company, Limited


08/06/15
20150216810 

Controlled release hydrocodone formulations


A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a c12/cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours..
Purdue Pharma L.p.


08/06/15
20150216809 

Controlled release hydrocodone formulations


A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a c12/cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours..
Purdue Pharma L.p.


07/16/15
20150197544 

Compositions comprising enzyme-cleavable oxycodone prodrug


The embodiments provide compound kc-8, n-1-[3-(oxycodone-6-enol-carbonyl-methyl-amino)-2,2-dimethyl-propylamine]-arginine-glycine-malonic acid, or acceptable salts, solvates, and hydrates thereof. The present disclosure also provides compositions, and their methods of use, where the compositions comprise a prodrug, compound kc-8, that provides controlled release of oxycodone.
Signature Therapeutics, Inc.


07/16/15
20150196611 

Pharmaceutical composition and methods for modulating immune system, preventing, pretreating and/or treating cancers


This invention provides a pharmaceutical composition for modulating immune system comprising at least one polysaccharide extracted from radix astragali, radix codonopsis, ganoderma sinense, or mixtures thereof, and their extraction process. The present invention further relates to a method of modulating immune system by applying said pharmaceutical composition to a subject suffering from cancers, and a method of preventing and/or pretreating and/or treating cancers in the subject, where said method comprises applying said pharmaceutical composition before/during chemotherapy..
Hong Kong Baptist University


07/09/15
20150191721 

Expression of maize codon optimized proteins in pseudomonas fluorescens


Compositions and methods for improving expression of a recombinant protein or polypeptide of interest in a host cell are provided. Compositions comprising a polynucleotide coding sequence for a btbooster are provided using a plant optimized system.
Dow Agrosciences Llc


07/09/15
20150190451 

Herbal composition and a the treatment of hyperlipidemia caused by excessive consumption of lamb


A composition and a method for treating hyperlipidemia caused by excessive consumption of lamb. The composition comprises in various parts: root of anhwei barberry, folium isatidis, garden erphorbia herb, aster ageratoides, vietnamese sophora root, codonopsis ianceolata, all-grass of snakefoot clubmoss, apanese stephania root, amur barberry root, thymifoious euphorbia herb, puff-ball, meadowrue root and rhizome, cottonrose hibiscus flower, common lantana leaf, herba orostachyos, japanese dock root, pubescent holly root, chinese brake herb, fruit of tree-of-heaven ailanthus, chinese iris seed, european verbena herb, datura seed, wild buckwheat rhizome, filliform cassytha herb, fig, radix cynanchi atrati, bittersweet herb, chinese pulsatilla root, spreading hedyotis herb, figwort root, herb of hygrometric boea, radix ardisiae crenatae, sowthistle tasselflower herb, weeping forsythia, roughhaired holly root, tree peony bark, membrane of chicken gizzard, carrot, medicated leaven, and radix glycyrrhizae.

07/09/15
20150190393 

Use of oxycodone for treating visceral pain


It is possible to effectively treat moderate to severe visceral pain by administering analgesic medications comprising the opioid oxycodone or pharmaceutically acceptable salts thereof. Visceral pain and especially acute (i.e.
Purdue Pharma L.p.


07/02/15
20150184250 

Kras primers and probes


The present invention provides oligonucleotide primers or probes for the detection of a mutation of the kras gene. The invention also provides a method for detecting a mutation in the kras gene using the oligonucleotide primers or probes disclosed therein.
Response Genetics, Inc.


07/02/15
20150184150 

Efficient, expansive, user-defined dna mutagenesis


The presently disclosed subject matter provides methods for the creation of one or more user-defined mutations that can be located anywhere in a target sequence, such as in a gene. These mutations can comprise single mutations, multiple mutations, or a comprehensive codon mutagenesis library, in which all possible single codon substitutions in a gene are created.
The Johns Hopkins University


07/02/15
20150182545 

Materials and methods for treating diseases caused by genetic disorders using aminoglycosides and derivatives thereof which exhibit low nephrotoxicity


Various aspects related to the preparation of congeners of the aminoglycosides gentamicin such as the congener c2 and using this compound or derivatives thereof and pharmaceutically active salts to treat diseases that involve genetic mutations which introduce a missense or premature stop codon into a gene. Still other aspects include treating human or animal patients with the gentamicin congener c2 and derivatives and pharmaceutical salt thereof to overcome, or to at least mitigate, the symptoms of disease and disorders such as some forms of becker's or duchenne muscular dystrophy, hurler's syndrome and cystic fibrosis that have as their etiology the presence of a premature stop codon in a gene whose proper expression is necessary for good health..
Indiana University Research And Technology Corp.


06/25/15
20150175672 

Process for designing diverged, codon-optimized large repeated dna sequences


This disclosure concerns methods for the design of synthetic nucleic acid sequences that encode polypeptide amino acid repeat regions. This disclosure also concerns the use of such sequences to express a polypeptide of interest that comprises amino acid repeat regions, and organisms comprising such sequences..
Dow Agrosciences Llc


06/25/15
20150174121 

Controlled release hydrocodone formulations


A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a c12/cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours..
Purdue Pharma L.p.




Codon topics: Hydrocodone, Nucleic Acid, Acetaminophen, Carboxylic Acid, Benzoic Acid, Genetically, Recombinant, Amino Acid, Nucleotide, Reverse Transcriptase Inhibitors, Reverse Transcriptase Inhibitor, Reverse Transcriptase, Antibodies, Base Sequence, Replication

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Codon for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Codon with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.858

4408

2 - 1 - 102